Enliven Therapeutics, Inc. Stock 12‑Month Price Target Raised to $70.9, Implies 19% Upside
Enliven Therapeutics, Inc. (ELVN) has seen its average 12-month price target raised from $65.8 to $70.9 by 10 analysts, suggesting a 19% potential upside from its Aug. 5 closing price. The consensus rating from 11 covering analysts remains a "Buy," with no hold or …